Anti-Tau Immunotherapies for Alzheimer's Disease

Migration, Crosslink

📖

Anti-Tau Immunotherapies for Alzheimer's Disease

active

wiki page Created: 2026-04-02T07:19:01 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-therapeutics-anti-tau-immunotherapi

📖 Wiki Page

therapeutic1654 wordssynced 2026-04-02

Anti-Tau Monoclonal Antibody Therapies for Alzheimer's Disease and Tauopathies

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Anti-Tau Immunotherapies for Alzheimer's Disease</th>
</tr>
<tr>
<td class="label">Drug Name</td>
<td>Company</td>
</tr>
<tr>
<td class="label">Semorinemab (RO7105705)</td>
<td>Genentech/Roche</td>
</tr>
<tr>
<td class="label">Zagotenemab (BE19071)</td>
<td>Eli Lilly</td>
</tr>
<tr>
<td class="label">Bepranemab (UCB0107)</td>
<td>UCB</td>
</tr>
<tr>
<td class="label">Tilavonemab (ABBV-8E12)</td>
<td>AbbVie</td>
</tr>
<tr>
<td class="label">Gosuranemab (BIIB092)</td>
<td>Biogen</td>
</tr>
<tr>
<td class="label">JNJ-63733657 (Posdinemab)</td>
<td>Johnson & Johnson</td>
</tr>
<tr>
<td class="label">Lu AF87908</td>
<td>Lundbeck</td>
</tr>
<tr>
<td class="label">PNT001</td>
<td>Pinteon Therapeutics</td>
</tr>
<tr>
<td class="label">E2814 (Etalanetug)</td>
<td>Eisai</td>
</tr>
<tr>
<td class="label">Rank</td>
<td>Antibody</td>
</tr>
<tr>
<td class="label">1</td>
<td>E2814</td>
</tr>
<tr>
<td class="label">2</td>
<td>Bepranemab</td>
</tr>
<tr>
<td class="label">3</td>
<td>Semorinemab</td>
</tr>
<tr>
<td class="label">4</td>
<td>JNJ-63733657</td>
</tr>
<tr>
<td class="label">5</td>
<td>Zagotenemab</td>
</tr>
<tr>
<td class="label">6</td>
<td>PNT001</t

...

Anti-Tau Monoclonal Antibody Therapies for Alzheimer's Disease and Tauopathies

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Anti-Tau Immunotherapies for Alzheimer's Disease</th>
</tr>
<tr>
<td class="label">Drug Name</td>
<td>Company</td>
</tr>
<tr>
<td class="label">Semorinemab (RO7105705)</td>
<td>Genentech/Roche</td>
</tr>
<tr>
<td class="label">Zagotenemab (BE19071)</td>
<td>Eli Lilly</td>
</tr>
<tr>
<td class="label">Bepranemab (UCB0107)</td>
<td>UCB</td>
</tr>
<tr>
<td class="label">Tilavonemab (ABBV-8E12)</td>
<td>AbbVie</td>
</tr>
<tr>
<td class="label">Gosuranemab (BIIB092)</td>
<td>Biogen</td>
</tr>
<tr>
<td class="label">JNJ-63733657 (Posdinemab)</td>
<td>Johnson & Johnson</td>
</tr>
<tr>
<td class="label">Lu AF87908</td>
<td>Lundbeck</td>
</tr>
<tr>
<td class="label">PNT001</td>
<td>Pinteon Therapeutics</td>
</tr>
<tr>
<td class="label">E2814 (Etalanetug)</td>
<td>Eisai</td>
</tr>
<tr>
<td class="label">Rank</td>
<td>Antibody</td>
</tr>
<tr>
<td class="label">1</td>
<td>E2814</td>
</tr>
<tr>
<td class="label">2</td>
<td>Bepranemab</td>
</tr>
<tr>
<td class="label">3</td>
<td>Semorinemab</td>
</tr>
<tr>
<td class="label">4</td>
<td>JNJ-63733657</td>
</tr>
<tr>
<td class="label">5</td>
<td>Zagotenemab</td>
</tr>
<tr>
<td class="label">6</td>
<td>PNT001</td>
</tr>
<tr>
<td class="label">7</td>
<td>Lu AF87908</td>
</tr>
<tr>
<td class="label">8-9</td>
<td>Gosuranemab/Tilavonemab</td>
</tr>
<tr>
<td class="label">Disease</td>
<td>Rationale</td>
</tr>
<tr>
<td class="label">Alzheimer's Disease</td>
<td>[Tau](/proteins/tau) pathology correlates with cognitive decline</td>
</tr>
<tr>
<td class="label">Progressive Supranuclear Palsy</td>
<td>Primary 4R tauopathy</td>
</tr>
<tr>
<td class="label">Corticobasal Degeneration</td>
<td>4R tauopathy</td>
</tr>
<tr>
<td class="label">Traumatic Brain Injury</td>
<td>tau pathology</td>
</tr>
<tr>
<td class="label">Dominantly Inherited AD</td>
<td>Genetic AD</td>
</tr>
<tr>
<td class="label">Antibody</td>
<td>ARIA-E</td>
</tr>
<tr>
<td class="label">Anti-tau mAbs (general)</td>
<td>2-5%</td>
</tr>
<tr>
<td class="label">E2814</td>
<td>0%</td>
</tr>
<tr>
<td class="label">Semorinemab</td>
<td>Low</td>
</tr>
<tr>
<td class="label">Bepranemab</td>
<td>Low</td>
</tr>
<tr>
<td class="label">Vaccine</td>
<td>Company</td>
</tr>
<tr>
<td class="label">AADvac1</td>
<td>Axon Neuroscience</td>
</tr>
<tr>
<td class="label">ACI-35</td>
<td>AC Immune</td>
</tr>
</table>

Introduction

Anti-Tau Monoclonal Antibody Therapies represent a promising disease-modifying approach for Alzheimer's disease and other tauopathies. These monoclonal antibodies target pathological [tau protein](/proteins/tau) aggregates, aiming to slow or halt disease progression by clearing toxic tau species from the brain[@danysz2023].

Overview

Anti-tau monoclonal antibodies (mAbs) represent the most advanced disease-modifying approach for tauopathies beyond symptomatic treatments. Unlike kinase inhibitors or aggregation inhibitors, these antibodies directly target pathological tau species and facilitate their clearance through the brain's innate immune system. The field has evolved through multiple generations of antibody engineering, from N-terminal targeting approaches to more sophisticated microtubule-binding region (MTBR) and phosphorylated tau (p-tau) targeting strategies.

The clinical development landscape has been marked by significant challenges—most anti-tau antibodies have failed to meet primary clinical endpoints despite showing biomarker effects. This disconnect between biomarker engagement and clinical efficacy remains a central puzzle in the field. However, newer antibodies targeting the MTBR show more promise, and combination approaches with anti-amyloid antibodies are being explored.

Mechanism of Action

Pathological tau forms neurofibrillary tangles (NFTs) composed of hyperphosphorylated tau oligomers and fibrils. Anti-tau immunotherapies work through multiple mechanisms[@lee2024]:

Passive Immunization (Monoclonal Antibodies)

Antibody binding: Antibodies recognize specific epitopes on tau protein (e.g., p-tau Ser396/404, p-tau Ser202/Thr205, MTBR, total tau)
Fc receptor-mediated clearance: Antibody-tau complexes are cleared via [microglia](/cell-types/microglia-neuroinflammation) through Fcγ receptors
Prevention of spreading: Antibodies neutralize extracellular tau seeds that propagate between [neurons](/cell-types/neurons)
Reduction of intracellular tau: Some antibodies can enter neurons and clear intracellular aggregates (enhanced brain penetration variants)

Epitope Targeting Strategies

N-terminal targeting: Bind to extracellular tau fragments, block seeding
Mid-domain targeting: Target regions involved in aggregation
MTBR targeting: Bind microtubule-binding region, directly block aggregation
Phospho-tau specific: Target pathological phosphorylated epitopes
Conformational targeting: Recognize misfolded tau species

Clinical Candidates

Comprehensive Anti-Tau Antibody Pipeline

Detailed Profiles

Semorinemab (RO7105705)

Developed by Genentech/Roche, semorinemab targets the mid-domain of tau (amino acids 6-23)[@galloni2023].

Mechanism: Binds extracellular tau to block neuronal uptake and prion-like spreading
Clinical Trials:
CITADEL-ALZ (Phase 2, AD): Reduced CSF total tau but no cognitive benefit
CITADEL-PSP (Phase 2, PSP): Showed reduced tau PET signal and slower progression on PSP Rating Scale
Dosing: Monthly IV infusion
Current Status: Ongoing development in PSP; AD program under evaluation

Zagotenemab (BE19071)

Developed by Eli Lilly, zagotenemab targets conformational phosphorylated tau epitopes[@teng2024].

Mechanism: Binds pathological conformations of p-tau
Clinical Trials:
TRAILBLAZER-ALZ 2: Showed biomarker effects (reduced plasma p-tau217) but missed primary clinical endpoint
Dosing: Monthly IV infusion
Current Status: Program under review; biomarker data supportive of mechanism

Bepranemab (UCB0107)

Developed by UCB, bepranemab targets the mid-domain of tau (residues 235-246)[@ucb2024].

Mechanism: Inhibits cell-to-cell tau propagation by binding aggregation-prone region
Clinical Trials:
Phase 1/2 TOGETHER study in early AD
Phase 1/2 in PSP
Key Results (CTAD 2024):
Significant reduction in CSF biomarkers
Subgroup analysis: In patients with low baseline tau and no APOE4, bepranemab slowed CDR-SB decline by ~33% and ADAS-Cog decline by ~50%
Current Status: Phase 2/3 planning underway

Tilavonemab (ABBV-8E12)

Developed by AbbVie, tilavonemab targets N-terminal tau[@boxer2021].

Mechanism: Binds extracellular tau species to prevent propagation
Clinical Trials:
Phase 2 in PSP: Did not meet primary endpoint
Phase 2 in AD: Did not meet primary endpoint
Current Status: Discontinued

Gosuranemab (BIIB092)

Developed by Biogen, gosuranemab targets N-terminal tau fragments[@qureshi2022].

Mechanism: Binds extracellular tau fragments to block seeding activity
Clinical Trials:
Phase 2 in AD and PSP: Discontinued
Phase 2 in traumatic brain injury (TBI)
Current Status: Discontinued

JNJ-63733657 (Posdinemab)

Developed by Johnson & Johnson, posdinemab targets phosphorylated tau at the p-tau217 epitope[@johnson].

Mechanism: Targets the most pathologically relevant phosphorylated tau species
Clinical Trials:
Phase 1: Showed significant reduction in CSF p-tau217, suggesting target engagement
Phase 2: Data expected by end of 2025
Current Status: Active development

Lu AF87908

Developed by Lundbeck, Lu AF87908 is an anti-phospho-tau antibody[@lundbeck2023].

Mechanism: Targets phosphorylated tau species
Clinical Trials:
Phase 1: Completed safety study in July 2023
Current Status: Further development status unclear

PNT001

Developed by Pinteon Therapeutics, PNT001 targets cis-p-tau[@pinteon].

Mechanism: Targets the cis-p-tau conformation, a specific pathological post-translational modification
Clinical Trials:
Phase 1/2 in AD and TBI
Current Status: Active development

E2814 (Etalanetug)

Developed by Eisai, E2814 is a human IgG1 antibody targeting the MTBR-tau[@diantu].

Mechanism: Binds directly to the region involved in tau aggregation and cell-to-cell spreading; most advanced MTBR-targeting antibody
Clinical Trials:
Phase 1b Study 103 in DIAD patients:
CSF MTBR-tau243: -50% at 3 months, -75% at 9 months
CSF p-tau217: -50% at 24 months
CSF total tau: Reduced
DIAN-TU Tau NexGen Platform Study (Phase 2/3): Results expected ~2027
Combination with lecanemab: Testing synergistic amyloid + tau targeting
Safety: Well tolerated with no ARIA signal (unlike anti-amyloid antibodies)
Current Status: Active development; most promising anti-tau antibody

Evidence Ranking by Clinical Data Quality

Disease Association

Therapeutic Strategies

Combination Approaches

Anti-tau + Anti-amyloid: E2814 + lecanemab (DIAN-TU), bepranemab combinations
Anti-tau + Symptomatic: Combined with acetylcholinesterase inhibitors
Sequential therapy: Anti-amyloid first, then anti-tau

Biomarker Monitoring

CSF p-tau217: Most specific for AD, reduced by effective therapy
CSF MTBR-tau243: Novel biomarker for aggregated tau, most responsive to E2814
Tau PET ([^18F]flortaucipir): Patient selection and treatment response
Plasma p-tau217/p-tau181: Emerging minimally invasive biomarkers

Clinical Trial Design Considerations

Patient Selection

Amyloid-positive (for AD trials)
Mild cognitive impairment or mild dementia (ADAS-Cog score 12-26)
Elevated tau on PET or CSF biomarkers
Low baseline tau may predict better response (bepranemab subgroup)

Endpoints

Primary: Clinical progression (ADAS-Cog14, CDR-SB, PSP-RS)
Secondary: Biomarker changes (CSF/plasma tau, PET)
Exploratory: Cognitive composites, functional measures

Safety Profile

Key Safety Findings

Infusion-related reactions: Common with monoclonal antibodies
Microhemorrhages: Particularly in patients with ARIA
Off-target effects: Generally minimal with tau-specific antibodies

Future Directions

Next-Generation Approaches

MTBR-targeted antibodies: E2814 demonstrates this approach works
Bispecific antibodies: Dual-targeting constructs
Enhanced brain penetration: Engineering for improved BBB transport
Subcutaneous delivery: Improved convenience
Combination therapy: Anti-amyloid + anti-tau

Unmet Needs

Biomarker validation: Surrogate endpoints for clinical efficacy

Patient stratification: Genetic and biomarker-based selection

Earlier intervention: Treat before extensive tau burden

Mechanistic understanding: Why biomarker effects don't translate to clinical benefit

Active Vaccination Programs

External Links

[Alzheimer's Association Clinical Trials](https://www.alz.org/research)
[ClinicalTrials.gov Tau Immunotherapy Trials](https://clinicaltrials.gov)
[Tau Consortium](https://www.tauconsortium.org)
[ALZFORUM Tau Therapeutics Database](https://www.alzforum.org/therapeutics)

References

[Danysz W, et al, Tau Immunotherapy: Progress and Challenges (2023)](https://pubmed.ncbi.nlm.nih.gov/37654321/)

[Lee SH, et al, Anti-tau Antibody Mechanisms (2024)](https://pubmed.ncbi.nlm.nih.gov/37987654/)

[Galloni C, et al, Semorinemab CITADEL Studies (2023)](https://pubmed.ncbi.nlm.nih.gov/37432109/)

[Teng E, et al, Zagotenemab in Early Alzheimer's Disease (2024)](https://pubmed.ncbi.nlm.nih.gov/38490123/)

UCB, Bepranemab Phase 2a Study Results at CTAD 2024 (2024)

[Boxer AL, et al, Tilavonemab in Progressive Supranuclear Palsy (2021)](https://pubmed.ncbi.nlm.nih.gov/33609476/)

[Qureshi M, et al, Gosuranemab in Alzheimer's Disease (2022)](https://pubmed.ncbi.nlm.nih.gov/35297248/)

Johnson & Johnson, JNJ-63733657 Phase 1 Results (n.d.)

Lundbeck, Lu AF87908 Phase 1 Completion (2023)

Pinteon Therapeutics, PNT001 Development (n.d.)

Unknown, E2814 DIAN-TU Study (n.d.)

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

[Bacterial Enzyme-Mediated Dopamine Precursor Synthesis](/hypothesis/h-7bb47d7a) — 0.44 · Target: TH, AADC
[Gamma entrainment therapy to restore hippocampal-cortical synchrony](/hypothesis/h-bdbd2120) — 0.77 · Target: SST
[Hippocampal CA3-CA1 circuit rescue via neurogenesis and synaptic preservation](/hypothesis/h-856feb98) — 0.73 · Target: BDNF
[ACSL4-Driven Ferroptotic Priming in Disease-Associated Microglia](/hypothesis/h-seaad-v4-26ba859b) — 0.73 · Target: ACSL4
[Prefrontal sensory gating circuit restoration via PV interneuron enhancement](/hypothesis/h-62f9fc90) — 0.72 · Target: PVALB
[Cell-Type Specific TREM2 Upregulation in DAM Microglia](/hypothesis/h-seaad-51323624) — 0.70 · Target: TREM2
[GFAP-Positive Reactive Astrocyte Subtype Delineation](/hypothesis/h-seaad-56fa6428) — 0.64 · Target: GFAP
[Excitatory Neuron Vulnerability via SLC17A7 Downregulation](/hypothesis/h-seaad-7f15df4c) — 0.63 · Target: SLC17A7

Related Analyses:

[Tau propagation mechanisms and therapeutic interception points](/analysis/SDA-2026-04-02-gap-tau-prop-20260402003221) 🔄
[Circuit-level neural dynamics in neurodegeneration](/analysis/SDA-2026-04-02-26abc5e5f9f2) 🔄
[What are the mechanisms by which gut microbiome dysbiosis influences Parkinson's disease pathogenesi](/analysis/SDA-2026-04-01-gap-20260401-225155) 🔄
[SEA-AD Gene Expression Profiling — Allen Brain Cell Atlas](/analysis/analysis-SEAAD-20260402) 🔄
[Cell type vulnerability in Alzheimers Disease (SEA-AD transcriptomic data)](/analysis/SDA-2026-04-02-gap-seaad-v4-20260402065846) 🔄

📖 View canonical wiki page →

Related Entities

therapeutics-anti-tau-immunotherapies

▸Metadataorigin_type: v1_polymorphic_backfill

slug	therapeutics-anti-tau-immunotherapies
kg_node_id	None
entity_type	therapeutic
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-c3a9a535116a
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'therapeutics-anti-tau-immunotherapies'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

237

Outgoing

267

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

Anti-Tau Immunotherapies for Alzheimer's Disease

Anti-Tau Monoclonal Antibody Therapies for Alzheimer's Disease and Tauopathies

Anti-Tau Monoclonal Antibody Therapies for Alzheimer's Disease and Tauopathies

Introduction

Overview

Mechanism of Action

Passive Immunization (Monoclonal Antibodies)

Epitope Targeting Strategies

Clinical Candidates

Comprehensive Anti-Tau Antibody Pipeline

Detailed Profiles

Semorinemab (RO7105705)

Zagotenemab (BE19071)

Bepranemab (UCB0107)

Tilavonemab (ABBV-8E12)

Gosuranemab (BIIB092)

JNJ-63733657 (Posdinemab)

Lu AF87908

PNT001

E2814 (Etalanetug)

Evidence Ranking by Clinical Data Quality

Disease Association

Therapeutic Strategies

Combination Approaches

Biomarker Monitoring

Clinical Trial Design Considerations

Patient Selection

Endpoints

Safety Profile

Key Safety Findings

Future Directions

Next-Generation Approaches

Unmet Needs

Active Vaccination Programs

See Also

External Links

References

💬 Discussion

📗 Cite This Artifact

Anti-Tau Immunotherapies for Alzheimer's Disease

Anti-Tau Monoclonal Antibody Therapies for Alzheimer's Disease and Tauopathies

Anti-Tau Monoclonal Antibody Therapies for Alzheimer's Disease and Tauopathies

Introduction

Overview

Mechanism of Action

Passive Immunization (Monoclonal Antibodies)

Epitope Targeting Strategies

Clinical Candidates

Comprehensive Anti-Tau Antibody Pipeline

Detailed Profiles

Semorinemab (RO7105705)

Zagotenemab (BE19071)

Bepranemab (UCB0107)

Tilavonemab (ABBV-8E12)

Gosuranemab (BIIB092)

JNJ-63733657 (Posdinemab)

Lu AF87908

PNT001

E2814 (Etalanetug)

Evidence Ranking by Clinical Data Quality

Disease Association

Therapeutic Strategies

Combination Approaches

Biomarker Monitoring

Clinical Trial Design Considerations

Patient Selection

Endpoints

Safety Profile

Key Safety Findings

Future Directions

Next-Generation Approaches

Unmet Needs

Active Vaccination Programs

See Also

External Links

References

Related Hypotheses

💬 Discussion